Journal
PEDIATRIC BLOOD & CANCER
Volume 62, Issue 6, Pages 1102-1105Publisher
WILEY-BLACKWELL
DOI: 10.1002/pbc.25299
Keywords
ALL; cancer pharmacology; chemotherapy; lymphoblastic lymphoma; pharmacokinetics
Categories
Ask authors/readers for more resources
Asparaginase, an enzyme used to treat acute lymphoblastic leukemia and related forms of nonHodgkin lymphoma, depletes asparagine, which leads to lymphoblast cell death. Unlike most chemotherapeutic agents, asparaginase is a foreign protein that can result in clinical allergy and/or silent hypersensitivity with production of neutralizing antibodies that inactivate asparaginase. In North America, asparaginase activity levels can now be obtained via a commercially available assay, for therapeutic drug monitoring and investigation of potential allergic reactions. Herein, we provide recommendations and a corresponding algorithm for the clinical application of this assay after treatment with pegaspargase to evaluate suspected hypersensitivity reactions and/or silent inactivation. Pediatr Blood Cancer 2015;62:1102-1105. (c) 2014 Wiley Periodicals, Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available